
    
      Study design: randomized single-blind control trial Study population: patient with
      unresectable hilar cholangiocarcinoma with obstructive jaundice who need hilar biliary
      stenting Primary endpoint: Biliary stent patency time Secondary endpoint: Patient survival
      Intervention

        1. Recruited patients randomly assigned into 2 groups, conventional and RFA group by sealed
           enveloped

        2. All patients receive endoscopic biliary stenting. Those in RFA group receive RFA before
           biliary stent.

        3. Monitor for adverse event during hospitalization and during follow up

        4. Follow up as outpatient in 4-weekly interval with monitoring of serum liver function
           test as routine
    
  